The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension | Zendy

Pantelis Sarafidis | Zendy; Anastasios N. Lasaridis | Zendy; P NILSSON | Zendy; Areti Hitoglou-Makedou | Zendy; Emmanouil Pagkalos | Zendy; John G. Yovos | Zendy; C. Pliakos | Zendy; A. Tourkantonis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension

Author(s) -

Pantelis Sarafidis,

Anastasios N. Lasaridis,

P NILSSON,

Areti Hitoglou-Makedou,

Emmanouil Pagkalos,

John G. Yovos,

C. Pliakos,

A. Tourkantonis

Publication year - 2005

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1016/j.amjhyper.2004.09.010

Subject(s) - medicine , rosiglitazone , glycemic , endocrinology , glibenclamide , type 2 diabetes mellitus , diabetes mellitus , blood pressure , type 2 diabetes , gliclazide , excretion , renal function , creatinine

Thiazolidinediones are antidiabetic agents that improve insulin sensitivity (IS). Accumulating data indicate that these agents provide beneficial effects beyond glycemic control, such as improvement in vascular function. The aim of this study was to determine the effect of rosiglitazone on urine albumin excretion (UAE) in patients with type 2 diabetes mellitus (DM) and hypertension.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research